Volume 4, Issue 10
Editorialp. 869
Improving our messages about research participation: a community-engaged approach to increasing clinical trial literacy
Author(s): Daniela B Friedman, Andrea Tanner, Sei-Hill Kim, Caroline D Bergeron, Caroline B Foster
Special Reportp. 873–879
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Author(s): Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Clinical Trail Perspectivep. 881–888
Encouraging young men\\\\\\\'s participation in mental health research and treatment: perspectives in our technological age
Author(s): Louise A Ellis, Kathryn L McCabe, Kitty A Rahilly, Mariesa A Nicholas, Tracey A Davenport, Jane M Burns & Ian B Hickie
Clinical Trail Outcomesp. 889–901
Therapies under investigation for treating Parkinsons disease psychosis
Author(s): Niem Tu Huynh & Philippe Huot
Review: Clinical Trail Outcomesp. 903–913
Advances in targeted therapy for melanoma: a focus on MEK inhibition
Author(s): April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomesp. 915–922
Antibody drug conjugates in lymphoma
Author(s): Nitya Nathwani & Robert Chen
Clinical Trail Outcomesp. 923–934
Topical diltiazem in management of chronic anal fissure: a review of the literature
Author(s): Roja Hadianamrei
Clinical Trail Outcomesp. 935–950
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer
Author(s): Kouji Izumi, Lei Li & Chawnshang Chang
Clinical Trail Outcomesp. 951–968
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Author(s): Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomesp. 969–977
Ramucirumab: a promising development in advanced non-small cell lung cancer
Author(s): Virginie Avrillon & Maurice Perol
Corrigendump. 1056
